The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Hironaga Satake
No relevant relationships to disclose
Makoto Tahara
Consultant or Advisory Role - Boehringer Ingelheim; Eisai; Merck Serono
Research Funding - Boehringer Ingelheim; Eisai; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult
Satoshi Mochizuki
No relevant relationships to disclose
Sadamoto Zenda
Consultant or Advisory Role - Bristol-Myers Squibb; Merck Serono
Research Funding - Merck Serono
Takashi Kojima
No relevant relationships to disclose
Hideaki Bando
No relevant relationships to disclose
Tomoko Yamazaki
No relevant relationships to disclose
Ken Kato
No relevant relationships to disclose
Satoru Iwasa
No relevant relationships to disclose
Yoshitaka Honma
No relevant relationships to disclose
Hiroki Hara
No relevant relationships to disclose
Tomoya Yokota
No relevant relationships to disclose
Satoshi Hamauchi
No relevant relationships to disclose
Naomi Kiyota
Consultant or Advisory Role - Bristol-Myers Squibb; Merck Serono
Takayuki Kii
No relevant relationships to disclose
Keisho Chin
No relevant relationships to disclose
Atsushi Ohtsu
No relevant relationships to disclose